Clinical Trial Update: Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma [Phase 2]

View source ↗

Summary

A multicenter Phase 2 dose-finding trial of CP-4055 in combination with sorafenib for metastatic malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CP-4055
• Sorafenib (Sorafenib)

Snippet

Sponsor: Clavis Pharma | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED